Ambu's revenues and earnings disappoint despite top-line growth
Growth in the second quarter is a little weaker than the consensus estimate, while the Danish medtech company’s profit has seen a sharp year-over-year drop.
by marketwire, translated by daniel pedersen
Despite a growing top line, Ambu’s second-quarter growth in financial year 2022/2023 looks a little weaker than what analysts had anticipated, for example sliding back from the profit of the same quarter a year before.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst sees Ambu endoscope sales as driving growth
For subscribers
Ambu finds new COO at biotech firm
For subscribers
Mexico plant weighs down Ambu's climate account
For subscribers
